In our study, the addition of anti-EGFR therapy to doublet chemotherapy resulted in numerically longer PFS and OS compared to anti-VEGF therapy in RAS/RAF wild-type right-sided colon tumors. This evidence concerns the gene EGFR and colonic neoplasm.